Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Cash (2016 - 2025)

OptimizeRx (OPRX) has disclosed Change in Cash for 16 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 240.06% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, up 2215.47% year-over-year, with the annual reading at $10.0 million for FY2025, 2215.47% up from the prior year.
  • Change in Cash hit $3.8 million in Q4 2025 for OptimizeRx, up from $2.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $71.8 million in Q1 2021 to a low of -$46.1 million in Q3 2022.
  • Historically, Change in Cash has averaged $642395.4 across 5 years, with a median of $624061.5 in 2021.
  • Biggest five-year swings in Change in Cash: soared 2070.07% in 2021 and later crashed 6068.58% in 2022.
  • Year by year, Change in Cash stood at -$374808.0 in 2021, then plummeted by 6068.58% to -$23.1 million in 2022, then soared by 117.0% to $3.9 million in 2023, then tumbled by 169.87% to -$2.7 million in 2024, then soared by 240.06% to $3.8 million in 2025.
  • Business Quant data shows Change in Cash for OPRX at $3.8 million in Q4 2025, $2.9 million in Q3 2025, and $12000.0 in Q2 2025.